知镜 Cognispect · 医学文献与研究工作台

Activin signaling inhibitor Sotatercept in pulmonary veno-occlusive disease: building a bridge to transplantation?

Mietzner M, Held M, Pfeuffer-Jovic E.
Respiratory medicine case reports · 2026-06-10 · PMID 42328597

文献摘要

Background Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary arterial hypertension (PAH). Its prognosis is considerably worse and no medical treatment has a proven efficacy. Vasodilating drugs for PAH may contribute to a pulmonary edema in PVOD. Sotatercept is the latest approved medical treatment for PAH with a unique mode of action and promising treatment effects. However, none of the clinical trials of sotatercept have included patients with PVOD, so the effect of sotatercept is unknown. Case description We report two cases of hereditary PVOD that were treated with sotatercept in addition to established pulmonary arterial hypertension therapy. Under treatment with sotatercept, both patients showed stabilization of clinical condition and gas exchange, accompanied by slight improvements in DLCOc and KCOc. Conclusions These two cases suggest that sotatercept may have a beneficial effect on disease stabilization in hereditary PVOD, as reflected by improvements in DLCOc and KCOc as well as stabilization of clinical status. Therefore, it may be a therapeutic option to stabilize patients with PVOD and potentially prolong the bridging time to lung transplantation.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。